

EUROPASS
CURRICULUM VITAE



PERSONAL INFORMATION

Name: SIMONA GURZU (GURZU-PRUNDARU)
Address: George Emil Palade University of Medicine, Pharmacy, Science and Technology
38 Ghe Marinescu Street, 540193, Targu-Mures, Romania (UMFST)
Contact: simona.gurzu@umfst.ro; simonagurzu@yahoo.com; decanat.medicina.en@umfst.ro
Nationality: Romanian
Date of birth: 31/07/1978 Gender: Female
Web of science ID: <https://www.webofscience.com/wos/author/record/269087>
Web of Science ResearcherID: AAD-2710-2019; EXW-3151-2022; DVZ-8816-2022
Publons ID: <https://publons.com/researcher/1228066/simona-gurzu>
ORCID ID: <https://orcid.org/0000-0003-3968-5118>
Scopus ID: <https://www.scopus.com/authid/detail.uri?authorId=23473551900>
SciProfiles ID: <https://sciprofiles.com/profile/1227333>
UEFISCDI/Brainmap ID: U-1700-036Q-0702 (<https://www.brainmap.ro/simona-gurzu>)
Gogle Academic link: <https://scholar.google.com/citations?user=PVZruu0AAAAJ&hl=ro>
Loop ID: 64628 (<https://loop.frontiersin.org/people/64628/overview>)
Researchgate link: <https://www.researchgate.net/profile/Simona-Gurzu>
RCA ID: <https://referencecitationanalysis.com/00000743>

OCCUPATIONAL FIELD - WORK EXPERIENCE

Dates, Occupation, and positions held

European Comission

2025 – Individual evaluator for HORIZON projects

The Romanian National Ministry of Education and Research

2024-2029 **Vice-President** of the “Romanian National Board of Confirmation of PhD and habilitation titles in Medicine” (**CNATDCU**)

From 2022- **Member in “Romanian Academy of Medical Sciences”**

2017-2024 **Member in CNATDCU**

2018-2024 **Projects Evaluator - Ministry of Innovation and Scientific Research (ANCS)**

2019-2020/2023-2024 **Projects Evaluator – Romanian Executive Agency for Higher Education, Research, Development, and Innovation (UEFISCDI)**

Romanian College of Physicians – Transylvania Branch

2023-2029 Elected member in the Committee on Discipline

George Emil Palade University of Medicine, Pharmacy, Sciences and Technology (PIC 930012818)

2024-2029 **Dean - Faculty of Medicine in English - FMLE**

with extension in Hamburg, Germany – UMCH

2024 *Founder of the Digitalized Center of Morphological Sciences*
 2023-2029 Member in the Senate of the University
 2023-2029 Responsible for recognition of international certificates - Faculty of Medicine in English
 From 2021 Coordinator of the Research Center for Oncopathology and Translational Medicine (CCOMT)
 2021 **Founder of the Research Center for Oncopathology and Translational Medicine (CCOMT)**
 From 2021- Member of the University Committee for Research and knowledge Exchange (UCRkE)
 2020-2024 **Vice-Dean – FMLE/UMCH**
 2020-2024 Head of Dean’s Committee of Scientific Research and of Residency
 2020-2029 **Member in the General Scientific Council of PhD School (IOSUD/CSUD)**
 2020-2024 Member in the Committee of Curricular activity
 2020-2029 Member in the Council of Faculty of Medicine in English
 2020-2022 Coordinator of COVID-related problems - Faculty of Medicine in English
 From 2016- **Head of Department of Pathology**
 2016-2029 Member in the Didactic Staff Council Department
 2015-2021 *Head of the Microscopy Department - Research Center (CCAMF)*
 From 2015- **Professor - Department of Pathology**
 2014-2020 Responsible for scientific education of master students (preclinical research)
 2014-2026 **Member in the Scientific Council of PhD School of Medicine (CSD)**
 2013-2015 Associate Professor - *Department of Pathology*
 From 2013 Scientific supervisor for PhD students (**habilitated doctor**)
 2012 Founder of the Molecular Oncopathology Laboratory
 2011-2013 Senior Lecturer- *Department of Pathology*
 2006-2011 Assistant Professor (Junior Lecturer) - *Department of Pathology*

Clinical Emergency County Hospital of Targu-Mures, Romania, Department of Pathology (PIC 900768288)

From 2022 - Member of the Ethical Committee of Clinical Research
 2021-2024 **Elected Member of the Ethical Council**
 From 2021- Member of the Emergency Situations Council
 From 2019 - Member of the HYPEC and Digestive Oncoteams
 2017 - **Foundation of Molecular Oncopathology Laboratory**
 From 2018 - Member of the Board of examining in-hospital deaths
 From 2017- Member of the Board of examining the maternal deaths
 From 2017- Member of the Medical Council
 From 2016- **Coordinator of the activity of fellows/residents in Pathology**
 From 2016- **Director of Clinical Department of Pathology**
 From 2014- **Consultant GI Pathologist**
 2010-2014 Specialist in Pathology
 2006-2010 Fellow/Resident in Pathology

National Institute of Oncology, Budapest, Hungary, Center of Tumors and Molecular Pathology

PhD coordinator - International cotutela – 2021-2027; Visiting researcher – 2006-2016

Seoul University, Guro Hospital, Department of Pathology

Visiting researcher – 2008-2009

Hamamatsu University, School of Medicine, Center of Tumors, Japan

Invited Associate Professor – 2014

Aurelios Augenzentrum Recklinghausen – Munich, Germany/University of Szeged, Hungary

PhD coordinator - International cotutela – 2021-2026

Semmelweis University - Budapest, Hungary

PhD coordinator - International cotutela – 2020-2025

Polytechnic University of Bucharest (UPB)

PhD coordinator - National cotutela – 2021-2024

Other internships/training programmes: 2019 – ECCO workshop, Santiago, Chile – inflammatory bowel diseases; 2017 – Tatabiocenter, Athens, Greece – next generation sequencing; 2016 - Technical University of Munich, Germany – molecular biology; 2015 – Institute of Pathology, Medical University of Graz, Austria – molecular biology; 2007 – Victor Babes University of Medicine, Timisoara, Romania – immunohistochemistry and angiogenesis.

NATIONAL AND INTERNATIONAL IMPACT

2025- ResearchGate Interest Score 1210 - higher than 93% of all ResearchGate members

2025-Included in the top 100 most cited authors – Journal of Imaging

2025-Included in the top 100 most cited authors – Advances in Dermatology and Allergology

2024-2025 Included in the top 100 most cited authors – The Surgery Journal

From 2019 – Frontiers journals “loop” – scientific score higher than 99% of Frontiers members

2019 – Publons Academy mentor certificate

From June 2018 – Included in the top 4% most read authors on Academia.edu.

2017, 2018 – Outstanding Contribution in Reviewing – Elsevier Reviewer Recognition

From 2018 – Highly Influential Peer reviewer database - Baishideng Publishing Group

2018-2020 – Certification of excellence in reviewing medical papers – Spandidos Publications

From 2017 – Member of Highly Influential Scientists of Baishideng Publishing Group database.

2017 - Included in the top 25% most cited PlosOne author

2014 - First data in Europe (Medline database) about Maspin protein expression in gastric cancer (only 21 papers were published before, by authors from Asia)

2014 – Designed by Biomed central as “highly accessed published paper”.

2012 – UNESCO-L’Oréal Laurate – For women in science programme

2008-2012 - First data in Medline database about Mena protein expression in colorectal cancer, cervical and salivary gland lesions

MEMBER IN PROFESSIONAL SOCIETIES

2021-present – *European Society of Digital and Integrative Pathology*

2021-present - *Romanian Society for Medical Oncology*

2019-present - *World Academy of Sciences*

2017-present - *American Romanian Academy of Arts and Sciences (ARA)*

2017-present - *European Chron’s and Colitis Organisation (ECCO)*

2016-present - *International Society for IHC and Molecular Morphology (ISIMm - founder)*

2014-present - *Romanian Society for Cell Biology*

2013-present - *European Society for Medical Oncology (ESMO) – ID 318029*

2006-present - *Romanian Society for Morphology and Pathology*

(Vice-President of Targu-Mures branch from 2019)

2006-present - *European Society of Pathology (ESP) – Membership number 0000005589*

2016-present - member in the ESP Working Groups: Digestive Diseases, Autopsy Pathology – **reviewer for the abstracts submitted for the 35th European Congress of Pathology – Dublin, Ireland;** IT (Computational), Molecular Pathology, Dermatopathology, Soft tissue and Bone Pathology

MAIN ACTIVITIES AND RESPONSIBILITIES

1. Research activity (Gastrointestinal Cancer, Epithelial mesenchymal transition, Angiogenesis, Immunohistochemistry, Molecular Pathology, Tumor histogenesis, Targeted therapy)

2. Methodological knowledge: microscopy, digital pathology, In situ Hybridization, PCR analysis, NGS

2. Clinical diagnosis in field of GI Tumor Pathology, especially colorectal and gastric cancer (Histopathology, Immunohistochemistry, In situ Hybridization, PCR analysis, Sanger sequencing, NGS)

3. Teaching activity: MD students-Romanian, Hungarian and English classes, PhD students, masters' students, scientific supervisor in MD and PhD theses

4. Administrative activities: CEO – Clinical Department of Pathology, Vice-Dean, Research projects - coordinator, coordinator of the Research Center - CCOMT

Fields of research: gastrointestinal cancer, targeted oncotherapy, epithelial mesenchymal transition, angiogenesis in tumor and non-tumour lesions, tumor lymphangiogenesis, tumor histogenesis, molecular biology in colorectal/gastric cancers/melanomas (*MSI, K-ras, BRAF, p53, CDH1, HER-2, Maspin, Mena*), immunohistochemistry, In Situ Hybridization (FISH), Sanger sequencing, NGS

EDUCATION AND TRAINING

Name and type of organization providing education and training:

University of Medicine and Pharmacy of Targu-Mures, Romania

Clinical County Emergency Hospital of Targu-Mures, Romania

Date and place: University of Medicine and Pharmacy of Tîrgu-Mures, Romania,
Faculty of General Medicine – MD student (1999-2005)

Responsibilities: - students' leadership from 1st to 6th year
- teaching activity at Chair of Pathology starting with the 5th year

MD thesis: *Morphological and immunohistochemical study of colorectal carcinoma*. Scientific coordinator: Prof. Ioan Jung, Head of Pathology Department of Clinical County Emergency Hospital of Tîrgu-Mures, Romania – 2005

Diploma: MD (2005). University of Medicine and Pharmacy of Tîrgu-Mures

Qualification: Medical doctor (MD) – September 2005

Resident/Fellow in Pathology - November 2005

– passed the National Residential Exam (certificate no 107/2005)

Date and place: University of Medicine and Pharmacy of Tîrgu-Mures, Romania - Doctoral School
PhD student (2005-2008)

PhD thesis: *Correlation between classical and modern prognostic factors, angiogenesis and lymphangiogenesis in colorectal carcinomas*. Scientific supervisors: Prof. Ioan Jung, Head of Pathology Department and of Doctoral School of University of Medicine and Pharmacy of Tîrgu-Mures, Romania and Prof. Zoltan Szentirmay, Head of Department of Pathology at National Institute of Oncology, Budapest, Hungary

Diploma: PhD (2008), graduated with "*summa cum laudae*"

Prize of '*Best Romanian PhD thesis in field of medicine*' (CNCSIS, 2010)

Qualification: MD, PhD (December 2008)

Date: University of Medicine and Pharmacy of Tîrgu-Mureş, Doctoral School –
Postdoctoral researcher (2008-2013)

Habilitation thesis: *The role of molecular pathology in the targeted therapy of cancer*

Diploma: Habilitated Doctor (2013)

Qualification: MD, PhD, Habilitated Doctor in Medical Sciences,
Scientific supervisor for PhD students (July 2013)

Number of coordinating PhD students: 2013-2025 - 9 in training and 6 PhD students get the PhD title

Date and place: Romanian National School of Public Health (2013-2014)

Diploma/Qualification: Certificate of Complementary Studies - Management of Public Health
Romanian Ministry of Health – Certificate No C-035843/24.09.2014

Name and Address of Employer

1. George Emil Palade University of Medicine, Pharmacy, Science and Technology;
540139 Gheorghe Marinescu 38 street, Targu-Mures, Romania Tel: (40-265) 21 31 27
Fax: (40-265) 21 04 07 E-mail: rectorat@umfst.ro, Website: <http://www.umfst.ro>
2. Clinical County Emergency Hospital of Targu-Mures, Romania
540136 Gheorghe Marinescu 50 street, Targu-Mures, Romania

Type of business or sector: medical and academic (academic pathologist, CEO)

PERSONAL SKILLS AND COMPETENCE

Native language: Romanian

Other languages: English (Profex Certificate in Advanced Medical English-C1; Elanguest Certificate –B2)
French, Italian

Self assessment

	Understanding		Speaking		Writing
	Listening	Reading	Spoken interaction	Oral presentation	Writing production
English	high level	high level	high level	high level	high level
French	high level	high level	intermediate level	beginner level	beginner level
Italian	high level	intermediate level	intermediate level	intermediate level	beginner level

Social Skills and competences:

Hobby: travel, poetry, painting, architecture, penguins' life

Organisational skills and competence

Organizing scientific conferences (current year)

1. The Medical Congress of Health and Education. 9-11 October 2025. Brasov, Romania - The scientific committee
2. International Congress MARISIENSIS. 22-23 May 2025. Targu-Mures, Romania
3. UMFST-UMCH Research Day. 4th of April 2025. Târgu-Mureş, Romania

4. MEDICUS - AMICUS Congress of MD students and fellows. 20-23 March 2025, Brasov, Romania
– The scientific committee and Organizing committee.

Computer skills and competences

Competent with all Microsoft Office programmes and experience with HTML, data bases access, Graph Pad InStat, digital counting with Image G NIH's computer assisted programme, MedCalc statistical software, photoshop, digital pathology


ADDITIONAL INFORMATION

A. Associate/Academic Editor - Scientific Journals

- 2021-2025 - Frontiers in Medicine – section Pathology. **IF 3.9 (Q1 WoS - JCI)**
<https://www.frontiersin.org/journals/medicine/editors>
- 2022-2025- International Journal of Molecular Sciences - Topical Advisory Panel – **IF 5.6 (Q1 WoS)**
- 2020-2025-Life - Basel – Topical Advisory Panel. **IF 3.2 (Q1 - WoS)**
- 2022-2025 – Analytical Cellular Pathology – Hindawi - **IF 2.6 (Q2 - WoS)**
- 2019-2025-Frontiers in Oncology – section Gastrointestinal: Colorectal Cancers. **IF 4.7 (Q2 WoS)**
<https://www.frontiersin.org/journals/oncology/editors>
- 2014-2025-Medicine-Lippincott. **IF 1.4 (Q2 WoS)**
<https://journals.lww.com/md-journal/Pages/editorialboard.aspx#BreastCancer>
- 2014-2025 – Acta Marisiensis – seria Medica. Indexed in Scopus and EBSCO
- 2023-2024 – BJC Reports (partner to the British Journal of Cancer) – Springer Nature
- 2021-2025 - BMC Cancer – Springer Nature - **IF 3.8 (Q2 - WoS)**
- 2022- Frontiers in Immunology. **IF 7.3 (Q1 web of science - WoS)**
- 2014-2021 – BMC Musculoskeletal Disorders. **IF 1.879 (Q2 WoS-2021)**

B. Guest Editor-Scientific Journals

- 2025 - International Journal of Molecular Sciences - Molecular Pathology and Treatment of Hepatocellular Carcinoma - **IF 4.9 (Q1 WoS)**
- 2025 – Current Issues in Molecular Biology – Special Issue – "Future Challenges of Targeted Therapy of Cancers. Second edition". **IF 3 (Q3 WoS)**
- 2025 – Oncology Research – Special issue - Gastroenteropancreatic Tumors: From Basic Research to Therapeutic Approach. **IF 4.1 (Q2 – WoS)**
- 2025 – Exploration of Digestive Diseases - Inflammatory Diseases of the Gastrointestinal Tract. Indexed in DOAJ
- 2024/2025 – Life – Special Issue - "Helicobacter pylori" **IF 3.4 (Q1 WoS)**
- 2023-2025 – International Journal of Molecular Sciences – Special Issue "Cardiovascular Diseases: Histopathological and Molecular Diagnostics" - **IF 4.9 (Q1 WoS)**
- 2024 – Cancers – Special Issue " Histopathology and Diagnosis of Gastrointestinal Tumors" – **IF 5.2 (Q2 - WoS)**
- 2024 – Applied Sciences – Special Issue "Advances in Gastrointestinal Cancer Research: A Molecular and Biological Perspective" – **IF 2.7 (Q2 - WoS)**
- 2024-2025 – Current Issues in Molecular Biology – Special Issue – "Future Challenges of Targeted Therapy of Cancers II". **IF 3 (Q3 – WoS)**
- 2023/2024 – International Journal of Molecular Sciences – Special Issue "The carcinogenetic potential of Human Papilloma Virus: from experimental studies to targeted therapy" - **IF 5.6 (Q1 WoS)**



2023/2024 - Frontiers in Bioscience-Landmark – Special Issue – “Gastrointestinal cancer: Pathogenesis, carcinogenesis and targeted therapies”. **IF 3.1** (Q3 – WoS)

2023/2024 – Current Issues in Molecular Biology – Special Issue – “Future Challenges of Targeted Therapy of Cancers”. **IF 3.1** (Q3 WoS)

2023 – International Journal of Molecular Sciences – Special Issue – “Advanced Research on Biomarkers in Gastrointestinal Cancer”. **IF 5.6** (Q1 WoS)

2023 – International Journal of Molecular Sciences – Special Issue – “Future Challenges of Targeted Therapy of Cancers”. **IF 5.6** (Q1 WoS)

2023-Life - Basel – Special Issue – “Pediatric Gastroenterology Research” **IF 3.253** (Q2 – WoS)

2022 – Gastrointestinal Disorders – Special issue - “Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms”. **IF 0.7**

2021/2022 – Journal of Oncology – Special Issue – “Colorectal Cancer: from Molecular Genetics to Diagnosis and Therapy”. **IF 4.375** (Q2 WoS) <https://www.hindawi.com/journals/jo/si/965785/>

2022 – International Journal of Molecular Sciences – Special Issue - “Molecular Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms”. **IF 5.923** (Q1 WoS) https://www.mdpi.com/journal/ijms/special_issues/molecular_diagnostics_biomarkers_gastrointestinal_neoplasms_12_published_papers

2020/2021 – Life-Basel – Special Issue - “Serum and tissue biomarkers in Cancer: A Translational Approach” **IF 3.817** (Q2 WoS)

2020/2021 – Journal of Oncology – Special Issue – “Gastric Cancer: from Molecular Genetics to Diagnosis and Therapy”. **IF 4.375** (Q2 WoS) <https://www.hindawi.com/journals/jo/si/425940/>

2019/2020 - BioMed Research International. Special Issue in section Oncology - “Tumor Cell Plasticity: From Tumorigenesis to Metastasis”. **IF 3.411** (Q2 WoS)

C. Topic Editor-Scientific Journals

2025 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers: Colorectal Cancer – “National Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and Treatment”. Co-edited with Alessandro Passardi – IRCCS, Medola, Italy; Rocco Ricciardi – Harvard Medical School; David Gibbons – Dublin, Ireland. **IF 3.5** (Q2 WoS)

2025 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers: Interplay between Environmental Drivers and Genetic or Epigenetic Predispositions on Gastrointestinal Cancer Evolution. Co-edited with Zhang Shaosen – Center for National Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China; Xudong Huang - Sun Yat-sen University Cancer Center (SYSUCC) Guangzhou, China and Caihong Wang Peking University People's Hospital Beijing, China. **IF 3.5** (Q2 WoS)

2024 - Frontiers in Pharmacology – Special Issue/Research Topic in section Pharmacology of Anti-Cancer Drugs – “Immune Checkpoints Regulatory Mechanisms and Immunotherapy Strategies in Gastrointestinal Tumors”. Co-edited with Rongxin Zhang and Qing Xi - Guangdong Pharmaceutical University - Guangzhou, China. **IF 5.6** (Q1 WoS)

2024 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers – “Advanced molecular targets in the diagnosis and treatment of gastrointestinal cancer: Vol II”. **IF 3.5** (Q2 WoS)

2022 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers – “Detection and characterization of gastrointestinal (early) cancer”. Co-edited with Andrej Wagner -

Paracelsus Medical University - Salzburg, Austria; Valeria Barresi -University of Verona, Italy; and Yuming Jiang - Stanford University, United States. **IF 6.244 (Q2 WoS)**

2021 - Frontiers in Oncology – Special Issue – “Advanced molecular targets in the diagnosis and treatment of gastrointestinal cancer”. **IF 6.244 (Q2 WoS)**

D. Member in Editorial Board-Scientific Journals

2024-2025 - BMC Cancer – Springer Nature - **IF 3.8 (Q2 - WoS)**

2020-2025 – Life-Basel – Reviewer board. **IF 3.2 (Q1- WoS)**

2021 -2025 - Pathology Research and Practice - Elsevier - **IF 2.8 (Q2 - WoS)**

2022-2025 - Oncology Letters. **IF 4.6 (Q2 - WoS)**

2023-2025 – Cancer Informatics – Editorial review board. Sage. **IF 2.4 (Q2 - WoS)**

2019-2025 - World Academy of Sciences Journal. **IF 1.5 (Q2 - WoS)**

2021-2025 - Romanian Journal of Morphology and Embryology. **IF 1.2 (Q4 web of science)**

2012-2025 - World Journal of Clinical Cases. **IF 1 (Q3 web of science)**

2024-2025 – Eurasian Journal of Medicine and Oncology – **IF 0.7 (Q3 web of science)**

2016-2025 – BMJ Case Reports. **IF 0.6 (Q3 web of science)**

2023-2025 – Healthcare in Low-Resource Settings. **IF < 0.**

2022-2025 – Journal of Exploratory Research in Pharmacology. Indexed in Index Copernicus

2019-2025 - World Journal of Gastrointestinal Pathophysiology. Indexed in PubMed

2019-2025 - Current Drug Research Reviews. Indexed in PubMed

2017-2025-Medicinski Glasnik-Indexed in Scopus

2015-2025 - Journal of Dermatological Research – Indexed in Google Scholar

2015-2023 – Cancer Translational Medicine - Wolters Kluwer- Indexed in EBSCO

2017-2018-Current Chemical Genomics & Translational Medicine-Indexed in PubMed

2016-2017-New Horizons in Clinical Case Reports – Indexed in Scopus

2016-2017 – Clinics in Oncology – Indexed in Indexed in ICMJE, Publons, Crossref

2013-2017 – Edorium Journal of Pathology – Indexed in J-Gate

2013-2017 – Global Journal of Oncologists – Savvy Press – Indexed in DRJI

2010-2011 - Journal of Cancer Research and Experimental Oncology

E. PUBLICATIONS

Papers in extenso published in WoS-indexed journals.....	181
Papers in extenso published in BDI-indexed journals.....	41
Other papers published in extenso	19
Papers in abstract published in WoS-indexed journals.....	104
Papers in abstract published and presented at other international conferences.....	62
Papers in abstract published and presented at national conferences.....	213
Books and chapters published in books	26
Total Impact factor (IF) from papers in extenso	389.82
Total Journal citation indicator (JCI) from papers in extenso-2017-2025.....	63.53
Total Impact factor from abstracts	559.73
Citations.....	2899 - Google Scholar
Hirsh-index.29-Google Scholar/25-ResearchGate/22-web of science/22-Scopus/i10-index	92



F. FOREIGN STUDY TRIPS (SCHOLARSHIPS)

1. **Munich, Germany**, June – July 2016 - UEG (United European Gastroenterology) Basic Science Course
2. **Hamamatsu- Japan**, July – August 2014 – Hamamatsu University, School of Medicine, Department of Pathology – Invited Associate Professor
3. **Budapest- Hungary**, February 2013 – National Institute of Oncology, Department of Molecular Biology
4. **Budapest- Hungary**, November 2010/July-August 2011/February 2012/July-August 2012 – National Institute of Oncology, Department of Molecular Biology - project PD 504/2010.
5. **Seoul, South Korea**, November 2008/May -June 2009 – Seoul University, Guro Hospital - project 09/30.05.2008, ANCS, Romania.
6. **Pecs-Hungary**, April 2009 – University of Pecs, Faculty of Medicine, Department of Public Health - project 6CB/2008, ANCS, Romania.
7. **Budapest- Hungary**, August – September 2008/February 2009 – National Institute of Oncology, Department of Molecular Biology - project 7CB/2008, ANCS, Romania
8. **Budapest- Hungary** July 2008 – National Institute of Oncology, Department of Molecular Biology - project TD 355/2008, CNCSIS, Romania
9. **Budapest- Hungary**, August 2007 – National Institute of Oncology, Department of Molecular Biology - project TD 505/2007, CNCSIS, Romania
10. **Budapest- Hungary**, October 2006 – National Institute of Oncology, Department of Molecular Biology - project 227/2006, CEEX, Romania.

G. SCIENTIFIC AND ADMINISTRATIVE PROJECTS

G.1. HEAD/TEAM COORDINATOR - NATIONAL GRANTS

1. **2025** – FEDR – 9,864.011 lei (2,000.000 EUR) – Devices for Modernization of the Departments of Pathology and Genetics – SCJU - <https://www.zi-de-zi.ro/2025/02/04/echipamente-de-ultima-generatie-pentru-diagnostic-precis-si-complex-al-cancerului-la-spitalul-clinic-judetean-de-urgenta-targu-mures/>
2. **2024** – MC, UEFISCDI – Code: PN-IV-P2-2.2-MC-2024-0605. Microsatellite instability status and PDL-1 expression in liposarcomas.
3. **2024** – MC, UEFISCDI – Code: PN-IV-P2-2.2-MC-2024-0785. ARSB, Maspin and TP53 gene expression in colorectal carcinoma.
4. **2019** - MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2019-2538. Plasmacytoid carcinomas of the stomach: the immunoprofile highlights the potential targeted therapy of these rare histological variants
5. **2019** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2019-2145. Scholarship for participation at the 63rd ECCO Educational workshop.
6. **2018-2022** – Proiect Complex de Cercetare de Frontieră – Romanian National Authority for Scientific research - PN-III-P4-ID-PCCF-2016-0006. GRAPHSENGASTROINTEST/Graphene-based stochastic sensors for molecular diagnosis of upper gastro-intestinal cancer
7. **2018** – MC, UEFISCDI - PN-III-P1-1.1-MC-2018-0233 - Bit's 9th annual World DNA And Genome Day. Molecular classification of carcinomas of the gastrointestinal tract – Practical issues.
8. **2017** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2017-1950 – No 536/18.12.2017. Gastric Burkitt lymphoma: a case report and literature review.
9. **2017** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2017-0197 – No 524/18.12.2017. 22nd World Congress on advances in oncology and 20th International Symposium on molecular medicine. Pitfalls in evaluation of gastrointestinal specimens: metastases mimicking primary tumors.

10. **2014-2020** - MECS-ANCSI. POC-A1-A1.1.4-E-2015. No 50/2016. ID: P_37_673. Technologies of tissue engineering for cardiac valve regeneration. VALVE-REGEN. Coordinator of the team of Pathology
11. **2014-2016** - UMFTGM-PO-CC-02-F01: Molecular particularities of early-staged and advanced-gastric cancer, emphasized in surgical and biopsic specimens of patients from Eastern Europe and Japan
12. **2012-2013** - Unesco-L'Oreal: Initiation of targeted therapy in Romanian patients diagnosed with colorectal cancer. National fellowship
13. **2010-2012** - PD, 504/2010, UEFISCDI: Molecular classification of colorectal cancers and testing of K-ras mutations, mandatory for targeted therapy
14. **2008** - TD, 355/2008, CNCSIS – The correlation between prognostic and predictive factors, angiogenesis, lymphangiogenesis and microsatellite instability in colorectal carcinomas
15. **2008** - MC, 85/2008, CNCSIS - The CD31, Endoglin and VEGF expression in non-metastatic colorectal carcinomas
16. **2007** - MD, 33/2007, CNCSIS: Angiogenesis and lymphangiogenesis in colorectal tumors
17. **2007** - TD, 550/2007, CNCSIS: Classical and modern prognostic factors in colorectal carcinomas

G.2. MEMBER IN INTERNATIONAL GRANTS

1. **2008-2009 – Romania-South Korea:** 09/2008, ANCS: Angiogenesis in acute respiratory distress syndrome
2. **2008-2009 - Romania-Hungary, Pecs:** 06/2008, ANCS: Mena immunoexpression in benign, premalignant and malignant epithelial lesions. NEOMENA.
3. **2008-2009 - Romania-Hungary, Budapest:** 07/2008, ANCS: Molecular classification of carcinomas and lymphomas using genetic methods in order to anticipate the results of treatment and to make an individualizing oncotherapy. NEOLIMF.

G.3. MEMBER IN NATIONAL GRANTS


1. **2024-2025 – PNRR project.** Role of HIV-1 matrix protein p17 variants in lymphomagenesis: development of new diagnostic tools and therapeutic approaches.
2. **2022-2023 - INEXT - PNRR project** for digital development of the professions of the future – Foundation of the Digital Center of Medical Morphological Sciences
3. **2022-2023 – POCU/826/4/9/138603.** Prevention, diagnosis, and therapy of cervical cancer in early stages.
4. **2021-2023 – PN-III-P4-ID-PCE2020-1540.** Novel C-reactive protein inhibitors and dissociation blockers for therapeutic use in cardiovascular disease
5. **2020-2022 - POS-UMFTGM-CC-19:** Parietex mesh particularities
6. **2017-2018 – Hungarian Academy of Science 136/2017 –** The epithelial-mesenchymal transition in tumors of the gastrointestinal tract.
7. **2017-2018 - Sapientia Hungariae Alapitvany – “A Collegium Talentum” programme –** contract 6677/2017
8. **2016-2020 - MECS-ANCSI. POC-A1-A1.1.4-E-2015. No 51/2016. ID: P_37_674.** C-reactive protein therapy for stroke-associated dementia. SAD-CRP
9. **2015-2016 - Biosintex SRL. 11379/2015.** Analysis of clinical and paraclinical parameters used for improvement of diagnostic and therapeutical management of patients with coxartrosis.

10. **2013-2016** - PN-II-ID-PCE-2012-4-0133 „Neuroprotection and angiogenesis: new molecular factors and delivery systems with potential therapeutic application”.
11. **2014-2016** - POS 2013. Foundation of the Advanced Research Center in field of Pharmaceutical and Medical Research, at University of Medicine and Pharmacy of Tirgu-Mures, Romania. CCAMF.
12. **2014-2015** - POSDRU/159/1.5/S/136893. Identification of the particularities of hereditary and sporadic diffuse gastric cancer through molecular and immunohistochemical examinations. Mentor.
13. **2014-2015** - Treepharm S.A. 1699/2014. The advantages and disadvantages of the ligasurterm techniques.

G.4. EVALUATOR OF NATIONAL GRANTS

1. **2024** - Romanian Executive Agency for Higher Education, Research, Development, and Innovation (UEFISCDI) - PED competition
2. **2023** - UEFISCDI - PNRR-Dotari-2023
3. **2018-2024** – Romanian National Ministry for Innovation and Scientific Research (ANCS). Funding of Excellency in research, development, and innovation (CDI) - Subprogramme 1.2 – Institutional performance.
4. **2016-2024** – L’Oreal and UNESCO-Romanian branch. Competition for national fellowship “Women in science”.
5. **2019, 2024** - UEFISCDI. Competition of research collaboration between Romania and France. UEFISCDI PN-III-P3-3.1-PM-RO-FR-2019. Certificate no 25/18.04.2019
6. **2017** – Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. Internal competition for the team grant award. Certificate no 3407/14.03.2017.

Date,
27/02/2026

Prof. Dr. Habil. Simona Gurz , MD, PhD

